Nearly 45% growth forecast for APAC respiratory syncytial virus market

25 November 2019

The respiratory syncytial virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from $36.88 million in 2018 to $1.48 billion by 2028 across the five growth markets (5GM; Australia, India, Japan, South Korea and urban China) in the Asia-Pacific (APAC) region.

According to analytics firm GlobalData’s latest report, ‘ Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028’, the main driver of growth will be the launch of new products to prevent medically-significant RSV infections, including the first products to be licensed for RSV in India and urban China.

Philippa Salter, pharma analyst at GlobalData, comments: “The level of unmet need in the RSV marketplace is high in India and urban China, where there are currently no prophylactic or therapeutic options. The launch of the first RSV products in 2023 in urban China and 2024 in India is expected to be a strong driver of growth for the 5GM over the forecast period, especially considering the large potential patient populations in these markets.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK